This startup wants to accelerate ‘precision medicine’ with its growing biological data platform

This startup wants to accelerate ‘precision medicine’ with its growing biological data platform

Publication date: Aug 13, 2019

Amplion, a startup that helps healthcare companies sort through biological data, closed a Series A fundraising round led by Greycroft with participation from existing investors Revolution’s Rise of the Rest Seed Fund and Imagen Capital Partners.

-Every week there are thousands of clinical trials as well as research articles being published,” said Dr. Amanda Enstrom, chief product officer at Amplion.

Amplion’s core product, called Biomarkerbase, combs through information published to resources such as ClinicalTrials. org or PubMed. gov and identifies therapeutically important biomarkers, which are molecules that indicate diseases and other biological states.

Amplion was co-founded by chief technology officer Adam Carroll and John Audette, who left the company in 2016.

Concepts Keywords
Adam Carroll Life sciences
Biomarker Drug development
Biomarkers Greycroft
Business Marketing Biomarker
CEO Cell biology
Clinical Trials Branches of biology
Drug Development Venture capital
Google Progress drug developers
Healthcare Healthcare
Microsoft Reins startup
Oracle
Pacific Northwest
Precision Medicine
PubMed
Rad
Thermo Fisher Scientific
Venture
Venture Capital

Semantics

Type Source Name
gene UNIPROT REST
gene UNIPROT CFLAR
disease MESH development
gene UNIPROT RRAD

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *